When was Oryzon Genomics, S.A.'s iadademstat study announcement made, and what does the study cover?

Oryzon Genomics, S.A. made the announcement on February 9, 2026. The study covers patients with residual, progressive or recurrent ES-SCLC after first-line systemic therapy.

What is iadademstat and how is Oryzon Genomics, S.A. testing it in this study?

Iadademstat is described by Oryzon Genomics, S.A. as a potent and selective LSD1 inhibitor. The study is evaluating it in combination with atezolizumab and stereotactic body radiation therapy (SBRT), followed by maintenance therapy with atezolizumab and iadademstat.

What does Oryzon Genomics, S.A.'s Phase Ib study aim to evaluate?

The open-label, non-randomised Phase Ib study will evaluate the safety, tolerability and efficacy of iadademstat combined with atezolizumab and SBRT. The trial is a dose-finding study.

Who is sponsoring and conducting Oryzon Genomics, S.A.'s iadademstat trial?

Yale University is sponsoring and conducting the trial. Dr Anne Chiang at Yale University is serving as the study's Principal Investigator.

What type of trial is Oryzon Genomics, S.A.'s study of iadademstat?

The trial is an open-label, non-randomised Phase Ib study. It is registered as NCT07113691 and is titled “Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy”.

What treatment combination is Oryzon Genomics, S.A. studying in extensive stage small cell lung cancer?

The study is evaluating iadademstat together with the immune checkpoint inhibitor atezolizumab and SBRT. The treatment is followed by maintenance therapy with atezolizumab and iadademstat.

How does Oryzon Genomics, S.A. explain the rationale for combining iadademstat with immunotherapy and radiotherapy?

Oryzon Genomics, S.A. CEO Dr Carlos Buesa said that combining LSD1 inhibition with immunotherapy and radiotherapy is a compelling strategy and that the trial may provide insights into iadademstat's potential role in addressing ES-SCLC. Dr Anne Chiang said the study aims to boost the immune response by adding radiation and iadademstat to immunotherapy.

What additional research will be carried out in Oryzon Genomics, S.A.'s iadademstat trial?

Dr Anne Chiang said the study will use paired biopsies to help researchers understand key events occurring in the tumour and its microenvironment. She also said the study aims to learn how to extend the benefit of immunotherapy to more people with small cell lung cancer.

What identifiers does Oryzon Genomics, S.A. provide for its securities?

Oryzon Genomics, S.A. provides the ISIN Code ES0167733015 and the ticker symbol ORY. The source describes the company as a clinical-stage biopharmaceutical company focused on epigenetics.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports first dosing in Yale-led Phase Ib iadademstat study for ES-SCLC

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports first dosing in Yale-led Phase Ib iadademstat study for ES-SCLC

Q: Which patients can be enrolled in Oryzon Genomics, S.A.'s iadademstat study?

The study will enrol patients with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy, with or without immune checkpoint inhibitor therapy. The trial is focused on patients whose disease is persistent, recurrent or progressive after first-line systemic therapy.

Published Monday, 09 February 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Operational update
Published: Monday, 09 February 2026
Source announcement: oryzon.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced an investigator-initiated Phase Ib study of iadademstat in ES-SCLC.

On February 9, 2026, the first patient was dosed in trial NCT07113691.
The trial evaluates iadademstat with atezolizumab and stereotactic radiation therapy for safety, tolerability and efficacy.
Yale University sponsors and conducts trial NCT07113691.
The company says the study will enroll patients with residual, progressive or recurrent ES-SCLC.

Patients previously received platinum-based chemotherapy, with or without immune checkpoint inhibitor therapy.

Investor FAQs

Oryzon Genomics, S.A. announced that the first patient had been dosed in an investigator-initiated Phase Ib dose-finding study of iadademstat in combination with radiotherapy and an immune checkpoint inhibitor for patients with extensive stage small cell lung cancer (ES-SCLC). The study is sponsored and conducted by Yale University.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in extensive stage small cell lung cancer
Published: Monday, 09 February 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…